[go: up one dir, main page]

DE602004029671D1 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit - Google Patents

(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Info

Publication number
DE602004029671D1
DE602004029671D1 DE602004029671T DE602004029671T DE602004029671D1 DE 602004029671 D1 DE602004029671 D1 DE 602004029671D1 DE 602004029671 T DE602004029671 T DE 602004029671T DE 602004029671 T DE602004029671 T DE 602004029671T DE 602004029671 D1 DE602004029671 D1 DE 602004029671D1
Authority
DE
Germany
Prior art keywords
pyridinyl
dichloro
analgetic
efficacy
analgetic efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029671T
Other languages
English (en)
Inventor
Michael J Buckley
Jianguo Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE602004029671D1 publication Critical patent/DE602004029671D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004029671T 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit Expired - Lifetime DE602004029671D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,555 US20040242641A1 (en) 2003-05-27 2003-05-27 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
PCT/US2004/015905 WO2004106342A1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number Publication Date
DE602004029671D1 true DE602004029671D1 (de) 2010-12-02

Family

ID=33450880

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029671T Expired - Lifetime DE602004029671D1 (de) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Country Status (21)

Country Link
US (1) US20040242641A1 (de)
EP (1) EP1626973B1 (de)
JP (1) JP4716999B2 (de)
KR (2) KR101238281B1 (de)
CN (1) CN1826344B (de)
AT (1) ATE485296T1 (de)
AU (1) AU2004243270B2 (de)
BR (1) BRPI0410808A (de)
CA (1) CA2526530C (de)
CY (1) CY1111946T1 (de)
DE (1) DE602004029671D1 (de)
DK (1) DK1626973T3 (de)
ES (1) ES2352199T3 (de)
MX (1) MXPA05012738A (de)
NZ (2) NZ543615A (de)
PL (1) PL1626973T3 (de)
PT (1) PT1626973E (de)
SI (1) SI1626973T1 (de)
TW (1) TWI332502B (de)
WO (1) WO2004106342A1 (de)
ZA (1) ZA200509601B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US7354937B2 (en) * 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
EP2083921A2 (de) 2006-09-04 2009-08-05 Neurosearch A/S Pharmazeutische kombinationen aus einem nikotinrezeptormodulator und einem mittel zur intensivierung kognitiver funktionen
US8222278B2 (en) * 2008-06-03 2012-07-17 Abbott Laboratories Treatment of attention-deficit/hyperactivity disorder
EP2491034B1 (de) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Kondensierte heterocyclische verbindungen als orexinrezeptormodulatoren
EP2491038B1 (de) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituierte octahy-dropyrrolo [3,4-c]pyrrole als orexinrezeptormodulatoren
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
TW201129361A (en) * 2010-01-20 2011-09-01 Abbott Lab Methods for treating pain
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EP4091634A1 (de) 2016-03-10 2022-11-23 Janssen Pharmaceutica NV Verfahren zur behandlung von depression unter verwendung von orexin-2-rezeptor-antagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
ES2305373T3 (es) * 1999-01-29 2008-11-01 Abbott Laboratories Derivados diazabiciclicos como ligandos del receptor nicotinico de la acetilcolina.
CN1348449A (zh) * 1999-04-26 2002-05-08 神经研究公司 杂芳基二氮杂环烷烃及其制备方法和应用
MXPA01011897A (es) * 1999-05-21 2002-06-21 Abbott Lab Aminoazaciclos heterociclicos substituidos utiles como agentes del sistema nervioso central.
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents

Also Published As

Publication number Publication date
CA2526530C (en) 2013-01-08
KR20120014235A (ko) 2012-02-16
KR20060015738A (ko) 2006-02-20
CY1111946T1 (el) 2015-11-04
TWI332502B (en) 2010-11-01
PL1626973T3 (pl) 2011-04-29
CN1826344A (zh) 2006-08-30
PT1626973E (pt) 2010-12-31
HK1092135A1 (en) 2007-02-02
ES2352199T3 (es) 2011-02-16
JP2007500220A (ja) 2007-01-11
DK1626973T3 (da) 2011-01-10
CA2526530A1 (en) 2004-12-09
ATE485296T1 (de) 2010-11-15
ZA200509601B (en) 2006-10-25
NZ543615A (en) 2009-04-30
CN1826344B (zh) 2013-03-06
AU2004243270A1 (en) 2004-12-09
US20040242641A1 (en) 2004-12-02
EP1626973A1 (de) 2006-02-22
SI1626973T1 (sl) 2011-01-31
MXPA05012738A (es) 2006-02-22
TW200510420A (en) 2005-03-16
AU2004243270B2 (en) 2009-12-17
WO2004106342A1 (en) 2004-12-09
KR101238281B1 (ko) 2013-03-04
EP1626973B1 (de) 2010-10-20
BRPI0410808A (pt) 2006-06-27
NZ588123A (en) 2012-04-27
JP4716999B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
MY133667A (en) Quinazoline ditosylate salt compounds
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2005107726A3 (en) Method for the treatment of back pain
WO2004006858A3 (en) Compounds, compositions, and methods employing same
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
WO2002066500A3 (de) ANTAGONISTEN FÜR Α4β7-INTEGRIN
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
WO2002030357A3 (en) Compounds and methods for modulating ccr4 function
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
EP1667685A4 (de) Chinazolin-kaliumkanalhemmer
WO2003063796A3 (en) Heterocyclic arylsulfonamidobenzylic compounds
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
NO20042846L (no) Derivater av 5-(pyridin-3-yl)-1-azabicyklo[3.2.1]oktan, fremstilling derav og anvendelse av de samme som terapeutiske midler
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
WO2004016604A3 (en) Azabicyclic compounds are central nervous system active agents
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
WO2000050023A8 (en) Use of tamoxifen and related compounds as clc3 blockers in the treatment of vascular diseases